story of the week
Risk of MACE With Tofacitinib vs TNF Inhibitors in Patients With Rheumatoid Arthritis With or Without a History of Atherosclerotic Cardiovascular Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of the Rheumatic Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Ann. Rheum. Dis 2022 Sep 22;[EPub Ahead of Print], C Charles-Schoeman, MH Buch, M Dougados, DL Bhatt, JT Giles, SR Ytterberg, GG Koch, I Vranic, J Wu, C Wang, K Kwok, S Menon, JL Rivas, A Yndestad, CA Connell, Z SzekaneczFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.